North America is expected to holda dominant position in the market, increasing focus of manufacturers on noveldrug development for ALS
North America is expected to holda dominant position in the AmyotrophicLateral Sclerosis Treatment Market, as major companies present in theregion are focusing on collaborations for product development. For instance, inJanuary 2018 Sangamo Therapeutics, Inc. and Pfizer Inc. collaborated for thedevelopment of a potential gene therapy using zinc finger protein transcriptionfactors (ZFP-TFs) for the treatment of ALS. Companies based in emergingeconomies of Asia Pacific are focusing on developing novel drugs for treatmentof ALS. For instant major companies such as Mitsubishi Tanabe PharmaCorporation and Takeda Pharmaceutical Company Ltd are developing drugs fortreatment of ALS.
Amyotrophic lateral sclerosis(ALS), also known as Lou Gehrig's disease and motor neuron disease (MND), is aneurodegenerative disease, affecting nerve cells in the brain and spinal cordthat controls voluntary muscles. The disease is progressive in nature, meaningit gets worse over time.
According to a study published inCenters for Disease Control and Prevention, in 2016, around 14,713 people werediagnosed with ALS in the U.S. and prevalence rate of ALS was 4.7 cases per100,000 people in 2012. The prevalence rate increased to 5.0 cases per 100,000people and around 15,908 people were diagnosed with ALS in 2013, according tothe same study.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1206
The increasing prevalence of ALSis in turn, expected to support growth of the amyotrophic lateral sclerosis(ALS) treatment market in the near future.
Approval of novel innovativedrugs is expected to boost growth in amyotrophic lateral sclerosis treatmentmarket
In May 2017, The U.S. Food andDrug Administration (FDA) approved Radicava (edaravone), an innovative drugused in the treatment of amyotrophic lateral sclerosis (ALS). This was thefirst drug to be approved after over 20 years since the last FDA-approved drugfor ALS. The approval of this drug would provide an additional option forpatients suffering from this deadly disease. Increasing incidence of ALS isexpected to increase the adoption rate of this drug, in turn, boosting marketgrowth. The drug has already been approved in Japan and South Korea in 2015.
Initiatives taken by someassociations to increase awareness about diagnosis and treatment of ALS amongpopulation is also expected to drive market growth during forecast period(2017-2025). For instance in 2014, the ALS Ice Bucket Challenge, a socialmedia–centered campaign, received extensive public visibility and createdincreased awareness of ALS. In 2015, a group of ALS organizations in the U.S.,including the ALS Association, Les Turner ALS Foundation, and ALS TherapyDevelopment Institute, re-introduced the Ice Bucket Challenge to raise furtherfunds and spread awareness about ALS among population.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/amyotrophic-lateral-sclerosis-treatment-market-1206
Major players are collaboratingwith various research institutes and companies for the development of drug foramyotrophic lateral sclerosis treatment
In December 2017, MitsubishiTanabe Pharma Corporation, Order made Medical Research Corporation and TransChromosomics Inc. have completed strategic collaboration for the development ofantibody drug to treat neurodegenerative diseases such as ALS. TakedaPharmaceutical Company Ltd. collaborated with Montreal Neurological Institutefor the discovery of new drugs for ALS in the same month. In 2016, Evotec andCelgene Corporation have entered into a strategic drug discovery for thedevelopment of new drugs for neurodegenerative diseases such as ALS. In 2013Janssen Research & Development, Division of Janssen Pharmaceutica NV, andJohnson & Johnson collaborated, with three prominent Belgian academicinstitutions and research centers for the discovery of new treatment drugs forneurodegenerative diseases such as ALS.
Major players operating in theglobal amyotrophic lateral sclerosis treatment market include Mitsubishi TanabePharma, Takeda Pharmaceutical Company Ltd., Sanofi S.A., and MylanPharmaceuticals Inc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1206
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
